ABSTRACT
H1-antagonists have similar efficacy in the treatment of patients with allergic rhinitis or urticaria; however, they are diverse with regard to their chemical structure (Fig. 1), clinical pharmacology, and potential for toxicity (1). The scientific foundation for using these medications with optimal effectiveness in all patient populations, including the very young, the elderly, and those with hepatic or renal dysfunction, or those taking other medications concurrently, is provided by results of pharmacokinetic and pharmacodynamic studies (2).
